CN101759628B - 乙炔基吲哚化合物 - Google Patents

乙炔基吲哚化合物 Download PDF

Info

Publication number
CN101759628B
CN101759628B CN2009102608650A CN200910260865A CN101759628B CN 101759628 B CN101759628 B CN 101759628B CN 2009102608650 A CN2009102608650 A CN 2009102608650A CN 200910260865 A CN200910260865 A CN 200910260865A CN 101759628 B CN101759628 B CN 101759628B
Authority
CN
China
Prior art keywords
compound
methyl
phenyl
butoxy
ethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009102608650A
Other languages
English (en)
Chinese (zh)
Other versions
CN101759628A (zh
Inventor
大元和之
板谷敏
中山孝介
竹内淳
藤田学
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of CN101759628A publication Critical patent/CN101759628A/zh
Application granted granted Critical
Publication of CN101759628B publication Critical patent/CN101759628B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
CN2009102608650A 2008-12-22 2009-12-21 乙炔基吲哚化合物 Expired - Fee Related CN101759628B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008325815 2008-12-22
JP2008-325815 2008-12-22

Publications (2)

Publication Number Publication Date
CN101759628A CN101759628A (zh) 2010-06-30
CN101759628B true CN101759628B (zh) 2013-02-27

Family

ID=42110130

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009102608650A Expired - Fee Related CN101759628B (zh) 2008-12-22 2009-12-21 乙炔基吲哚化合物

Country Status (18)

Country Link
US (1) US8115014B2 (enExample)
EP (1) EP2206698B1 (enExample)
JP (2) JP5012884B2 (enExample)
KR (1) KR101464778B1 (enExample)
CN (1) CN101759628B (enExample)
AU (1) AU2009250960C1 (enExample)
BR (1) BRPI0905601A2 (enExample)
CA (1) CA2688614C (enExample)
DK (1) DK2206698T3 (enExample)
ES (1) ES2387185T3 (enExample)
IL (1) IL202869A (enExample)
MX (1) MX2009013926A (enExample)
NZ (1) NZ582208A (enExample)
PL (1) PL2206698T3 (enExample)
PT (1) PT2206698E (enExample)
RU (1) RU2505531C2 (enExample)
TW (1) TWI469965B (enExample)
ZA (1) ZA200909096B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201229038A (en) 2010-06-21 2012-07-16 Ono Pharmaceutical Co Novel crystalline form of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylpheny)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
KR101171790B1 (ko) 2010-07-30 2012-08-13 현대자동차주식회사 인출식 자전거 캐리어
ES2612492T3 (es) 2010-12-28 2017-05-17 Sanofi Nuevos derivados de piridiminas, su preparación y su utilización farmacéutica como inhibidores de fosforilación de AKT (PKB)
EP2537866A1 (en) * 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
CN103893146A (zh) * 2012-12-25 2014-07-02 天津药物研究院 含福多司坦缓释剂型
US11427591B2 (en) * 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
WO2021221111A1 (ja) * 2020-04-30 2021-11-04 国立大学法人京都大学 Ｒｎａウイルス関連疾患の予防又は治療剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128424A (zh) * 2005-02-25 2008-02-20 小野药品工业株式会社 吲哚化合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (enExample) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
JPH01192476A (ja) 1988-01-25 1989-08-02 Kawasaki Steel Corp 溶接鋼管の製造方法
US5229413A (en) * 1989-05-05 1993-07-20 G. D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
US5137910A (en) * 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
CA2019335C (en) 1989-06-27 2000-08-01 Mitoshi Konno Phenylalkan (en)oic acids
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
WO1994022821A1 (en) * 1993-04-05 1994-10-13 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives as testosterone 5 alpha-reductase inhibitors
ATE186528T1 (de) 1995-10-10 1999-11-15 Pfizer Indol-carbamate als leukotriene antagonisten
FR2766824B1 (fr) 1997-07-30 1999-09-10 Adir Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
AU2001270200A1 (en) 2000-06-27 2002-01-08 Smith Kline Beecham Corporation Fatty acid synthase inhibitors
JP2003025362A (ja) 2001-07-18 2003-01-29 Nippon Tokushu Toryo Co Ltd 通気性を有する発泡プラスチック及びその製法
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US7125906B2 (en) 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
WO2003091215A1 (en) 2002-04-23 2003-11-06 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2004099192A2 (en) 2003-04-30 2004-11-18 The Institutes Of Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP1661892B1 (en) * 2003-09-01 2013-07-24 Ono Pharmaceutical Co., Ltd. Condensed ring compound and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128424A (zh) * 2005-02-25 2008-02-20 小野药品工业株式会社 吲哚化合物及其用途

Also Published As

Publication number Publication date
RU2505531C2 (ru) 2014-01-27
MX2009013926A (es) 2010-06-22
JP5012884B2 (ja) 2012-08-29
US20100160647A1 (en) 2010-06-24
KR20100074036A (ko) 2010-07-01
KR101464778B1 (ko) 2014-11-24
JP2012144546A (ja) 2012-08-02
JP2010168359A (ja) 2010-08-05
NZ582208A (en) 2011-05-27
AU2009250960A1 (en) 2010-07-08
RU2009147506A (ru) 2011-06-27
ES2387185T3 (es) 2012-09-17
AU2009250960C1 (en) 2014-01-23
ZA200909096B (en) 2010-09-29
CN101759628A (zh) 2010-06-30
AU2009250960B2 (en) 2013-09-05
US8115014B2 (en) 2012-02-14
PT2206698E (pt) 2012-08-03
CA2688614A1 (en) 2010-06-22
EP2206698A1 (en) 2010-07-14
IL202869A (en) 2015-02-26
CA2688614C (en) 2015-01-06
PL2206698T3 (pl) 2012-12-31
TWI469965B (zh) 2015-01-21
BRPI0905601A2 (pt) 2012-05-02
EP2206698B1 (en) 2012-07-18
TW201026664A (en) 2010-07-16
DK2206698T3 (da) 2012-08-27

Similar Documents

Publication Publication Date Title
CN101759628B (zh) 乙炔基吲哚化合物
CA2599348C (en) Indole compound and use thereof
EP2583964B1 (en) New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid
EP1661892B1 (en) Condensed ring compound and use thereof
HK1178883B (en) New crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130227

Termination date: 20171221